Bacteremia

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

Retrieved on: 
Monday, July 20, 2020

This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.

Key Points: 
  • This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.
  • Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.
  • At ContraFect, we remain committed to developing superior therapeutic agents with the potential to improve clinical outcomes and save lives.
  • Invasive P. aeruginosa infections, including ventilator-associated pneumonia, blood stream infections, complicated urinary tract infections, and infections following surgery carry some of the highest rates of mortality among hospital acquired infections.

Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections

Retrieved on: 
Wednesday, June 17, 2020

Armata will use the award to partially fund a Phase 1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections.

Key Points: 
  • Armata will use the award to partially fund a Phase 1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections.
  • Drug-resistant S. aureus bacteremia infections carry mortality rates as high as 40%, reflecting the urgent need for novel and improved treatment options."
  • Because of the impact of COVID-19 on the Company's development programs, Armata does not believe the clinical trial will initiate prior to mid-2021.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections

Retrieved on: 
Wednesday, June 10, 2020

In addition, HelixBind announced that Dr. Melvin Weinstein, a leading authority in the field of blood cultures, is joining the companys Clinical Advisory Board.

Key Points: 
  • In addition, HelixBind announced that Dr. Melvin Weinstein, a leading authority in the field of blood cultures, is joining the companys Clinical Advisory Board.
  • HelixBind was awarded the grant from the NIH to expand the capabilities of RaPID, its direct-from-blood platform for the identification and characterization of bloodstream infections.
  • The new grant from the NIH will help us advance our platform and Dr. Weinsteins expertise will provide HelixBind with important guidance for our product development.
  • HelixBind is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis.

FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Retrieved on: 
Monday, June 1, 2020

Shionogi submitted the sNDA for FETROJA for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.

Key Points: 
  • Shionogi submitted the sNDA for FETROJA for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.
  • Safety was investigated up to 28 days after the end of treatment unless there was an ongoing serious adverse event(s).
  • The safety and efficacy of FETROJA have not been established for the treatment of nosocomial pneumonia, bloodstream infections or sepsis.
  • Reserve FETROJA for use in patients who have limited or no alternative treatment options for the treatment of cUTI.

Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®

Retrieved on: 
Tuesday, May 26, 2020

Through the Expanded Access protocol, an infected central venous catheter can now be treated with Citius' Mino-Lok, potentially avoiding the need for the removal and replacement procedure.

Key Points: 
  • Through the Expanded Access protocol, an infected central venous catheter can now be treated with Citius' Mino-Lok, potentially avoiding the need for the removal and replacement procedure.
  • Given the challenges at today's hospitals, the patients, the hospital staff, and the hospital system at large stand to benefit greatly from free access to the Mino-Lok solution.
  • Mino-Lok is currently in a Phase 3 clinical trial for the treatment of central line-associated bloodstream infections (CLABSIs).
  • CLABSIs/CRBSIsare very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge.

ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

Retrieved on: 
Tuesday, May 26, 2020

The private placement is contingent upon the closing of ContraFects public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.

Key Points: 
  • The private placement is contingent upon the closing of ContraFects public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.
  • All shares in the private placement are to be sold by ContraFect.
  • ContraFect intends to use the net proceeds of the private placement to continue funding its Phase 3 DISRUPT trial of exebacase (CF-301) in Staph aureus bacteremia, including right-sided endocarditis.
  • Examples of forward-looking statements in this release include, without limitation, statements regarding the private placement or the public offering of ContraFects common stock and warrants.

T2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards

Retrieved on: 
Tuesday, May 19, 2020

LEXINGTON, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.(NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the Best New Technology Solution - Diagnostics" award for its T2Bacteria Panel solutionin the fourth annual MedTech Breakthrough Awards program.

Key Points: 
  • LEXINGTON, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.(NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the Best New Technology Solution - Diagnostics" award for its T2Bacteria Panel solutionin the fourth annual MedTech Breakthrough Awards program.
  • But, with swift diagnosis and treatment, which our T2Bacteria Panel helps facilitate, we can help reduce these numbers for patients with bloodstream infections and improve patient outcomes.
  • The MedTech Breakthrough Award is one more addition to the Companys growing list of accolades and milestones.
  • T2 Biosystems products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, and the T2ResistancePanel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology.

Catheter-Related Bloodstream Infection (CRBSI) Pipeline Insights, 2020 - Therapeutics, Products, Drugs, Companies, and More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 5, 2020

The "Catheter-related Bloodstream Infection (CRBSI) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Catheter-related Bloodstream Infection (CRBSI) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Catheter-related bloodstream infection (CRBSI) market.
  • A detailed picture of the Catheter-related bloodstream infection (CRBSI) pipeline landscape is provided, which includes the disease overview and Catheter-related bloodstream infection (CRBSI) treatment guidelines.
  • The assessment part of the report embraces in-depth Catheter-related bloodstream infection (CRBSI) commercial assessment and clinical assessment of the Catheter-related bloodstream infection (CRBSI) pipeline products from the pre-clinical developmental phase to the marketed phase.

Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

Retrieved on: 
Wednesday, April 8, 2020

The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.

Key Points: 
  • The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.
  • This initiative seeks to ensure continuity of the independent study and not add to infectious disease pressures for beds around the country.
  • Recce Chairman Dr. John Prendergast said, The formalization of the clinical trial agreement is a major milestone towards advancing RECCE 327 through the clinic.
  • RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis derived from Escherichia coli and Staphylococcus aureus bacteria.

Global Catheter-Related Bloodstream Infection (CRBSI) Industry Insights, Epidemiology, and Outlook to 2028

Retrieved on: 
Tuesday, March 24, 2020

The catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Key Points: 
  • The catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
  • This section provides glimpses of the catheter-related bloodstream infection epidemiology in the global market.
  • The drug chapter segment of the catheter-related bloodstream infection report encloses the detailed analysis of catheter-related bloodstream infection marketed drugs and late stage (phase III) pipeline drugs.
  • A detailed review of catheter-related bloodstream infection market; historical and forecasted is included in the report, covering the global drug outreach.